Announcement: FDA Advisory Panel Endorses Moderna mRNA Flu Vaccine After Earlier Controversy

Last updated: 19/07/2026 15:30

0 Min Read

The FDA's Vaccines and Related Biological Products Advisory Committee endorsed Moderna's seasonal mRNA influenza vaccine in June 2026, resolving the regulatory pathway after earlier public controversy. The endorsement represents the first seasonal mRNA flu vaccine to reach this approval milestone. — Photo by Maksim Goncharenok on Pexels (Pexels License)

1 min read|50 words

The FDA's VRBPAC has endorsed Moderna's seasonal mRNA flu vaccine, marking the first mRNA influenza vaccine to reach this regulatory milestone. The endorsement follows public controversy earlier this year and paves the way for potential FDA licensure before the 2026–2027 flu season.

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Announcement

📰 Read the full article: FDA Advisory Panel Endorses Moderna mRNA Flu Vaccine After Earlier Controversy →

Share This Article

ByProf. Giorgi Pkhakadze

Follow:

Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Announcement: FDA Advisory Panel Endorses Moderna mRNA Flu Vaccine After Earlier Controversy

Submit Your Paper →

Alcohol Suppresses Heart Rate Variability During Sleep Across All Fitness Levels

Exercise’s True Power: A Systematic Review Shows Mitochondrial Remodeling, Not Just Volume, Drives Fitness Gains

Egg consumption linked to 27% lower Alzheimer’s risk in large multi-cohort study

Submit Your Paper to GMJ

Company

You Might Also Like